tirzepatide and losartan Weight-loss drug may lower heart failure deaths Sublingual Tirzepatide - An Overview

Considerations for long-term use GLP-1 drugs for weight loss aren't a quick fix

Change history 24 June 2026 The original article was revised due to update in Funding Information

That said, a real-world analysis by Prime Therapeutics and Magellan Rx looked at integrated pharmacy and medical claims data from 16 million commercially insured members and found that a whopping 68% had stopped taking their GLP-1s after just one year

An AI chatbot for patient engagement and automated insurance pre-checks are increasingly essential for clinics looking to scale

Different mechanism, different risk profile

Highly recommend for its quick results